1. Home
  2. Mental Health
  3. Grass Valley, CA
  4. Erowid Center

Erowid Center

Erowid Center has an America's Best Score of 58 out of 100, based on its 2024 Form 990, below the 60-point bar to be ranked.

  • Grass Valley, CA
  • Tax-exempt since 2007
  • EIN: 20-3256212
erowidcenter.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
58OF 100 Not ranked Below the 60-point bar How this score is calculated

Organization summary

Erowid Center is a 501(c)(3) organization, classified under Mental Health (NTEE F99). Contributions are tax-deductible.

1116 Box Po, Grass Valley, CA 95945-0000

Among the 5 scored mental health organizations in Grass Valley, Erowid Center holds 9.7 months of operating reserves (peer median 3.7 months), runs a typical yearly deficit of 11.8% (peers: surplus of 8.7%), and has grown spending 1.5% a year (peers: grown spending 25.1% a year).

In fiscal year 2024 it reported $423,518 in revenue and $660,937 in expenses, with contributions making up 61.6% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2024 Form 990

To provide & facilitate access to objective, accurate, and non-judgmental information about psychoactive plants chemicals, drugs, technologies, and related issues. Erowid also supports and trains information providers and assists medical, legal, and scientific experts in developing resources.

Largest programs · fiscal year 2024

  • Erowid Center runs a laboratory drug checking program that analyzes the contents of street samples of psychoactive drugs, including: novel psychoactive substances (NPS); stimulants and euphoric stimulants; psychedelics; research chemicals; street heroin; fentanyl; and other opioids; as well as commercial and counterfeit pharmaceuticals. Samples are tested at a licensed laboratory and the results a… Read more

    Erowid Center runs a laboratory drug checking program that analyzes the contents of street samples of psychoactive drugs, including: novel psychoactive substances (NPS); stimulants and euphoric stimulants; psychedelics; research chemicals; street heroin; fentanyl; and other opioids; as well as commercial and counterfeit pharmaceuticals. Samples are tested at a licensed laboratory and the results are published online at DrugsData.org. Erowid's DrugsData project also collects, manages, reviews, and presents laboratory-testing results from other US and international organizations. This information is made publicly available to help harm-reduction efforts, medical personnel, researchers, and the public. In 2024, 1,001 samples were tested through this project and 199 unique substances were detected. These results were published alongside results for 799 samples tested by other organizations. An average of 30,000 result pages were viewed per day, with an average 15,000 unique visitors per day. Results were regularly published on social media to Erowid's more than 180,000 followers. Erowid continued its partnerships with research groups doing lab validation of on-site analytical tools such as compact FTIR and fentanyl and xylazine test strips. A portion of the expenses and revenue associated with DrugsData research are included in the Drug Trend & Novel Psychoactive Substance and Research program services described below. This service was interrupted on April 10, 2024, due to an unexpected regulatory change and was unable to conduct operations through the end of 2024.

    $191,552 spent · 34.7% of program spending
  • Erowid Center develops, maintains, and provides free access to an online collection of more than 96,700 documents, images, and other media files related to psychoactive plants and drugs. The collection contains information, essays and articles authored by a broad spectrum of contributors including health care professionals, substance abuse counselors, toxicologists, chemists, therapists, law enfor… Read more

    Erowid Center develops, maintains, and provides free access to an online collection of more than 96,700 documents, images, and other media files related to psychoactive plants and drugs. The collection contains information, essays and articles authored by a broad spectrum of contributors including health care professionals, substance abuse counselors, toxicologists, chemists, therapists, law enforcement agents, lawyers, anthropologists, experiential experts, writers, media, educators, and the general public. Note that Erowid's Experience Reports project is tracked as a separate program service. Erowid also shared information via social media accounts on Twitter, Instagram, and Facebook.

    $119,090 spent · 21.6% of program spending
  • Erowid Center's mission includes collecting, organizing, and preserving resources about psychoactives for the historical record. In 2024, Erowid's primary archiving project was the Shulgin Collection. Erowid nearly completed digitizing Alexander and Ann Shulgin's personal papers, audio recordings, and documents. Erowid also organized, identified, and created metadata for digitized files. By the en… Read more

    Erowid Center's mission includes collecting, organizing, and preserving resources about psychoactives for the historical record. In 2024, Erowid's primary archiving project was the Shulgin Collection. Erowid nearly completed digitizing Alexander and Ann Shulgin's personal papers, audio recordings, and documents. Erowid also organized, identified, and created metadata for digitized files. By the end of the year, Erowid had created index entries for 55,000 scanned documents in the collection of around 230,000 total scanned items. Erowid Center maintains a physical space designed to allow processing of historical archive collections (organizing, scanning, photographing, and digitizing) as well as permanent storage of some library archives/collections.

    $110,825 spent · 20.1% of program spending
  • 4. Research, Surveys, & Research Improvement - Research, Surveys, & Research Improvement - In 2024, Erowid co-authored 4 published peer-reviewed journal articles. We participated in writing and submitting two additional papers, not published in 2024. We worked on multiple scientific/medical research projects as part of the Lab Validation subproject of our DrugsData program. Erowid improves scienti… Read more

    4. Research, Surveys, & Research Improvement - Research, Surveys, & Research Improvement - In 2024, Erowid co-authored 4 published peer-reviewed journal articles. We participated in writing and submitting two additional papers, not published in 2024. We worked on multiple scientific/medical research projects as part of the Lab Validation subproject of our DrugsData program. Erowid improves scientific, medical, and sociological information about psychoactive substances and those who use them by promoting participation in studies and surveys produced by academics, educational institutions, and related organizations. Erowid works directly with scientists-in areas where we have specialized knowledge-to help design credible studies and provide editing, reviewing, and fact-checking for resulting academic publications. Several additional papers were published in academic journals using Erowid's Experience Vault data as a major part of their primary dataset. Erowid Center's resources are referenced in hundreds of journal articles, books, and media articles each year.

    $44,319 spent · 8.0% of program spending
  • 5. Drug Trend & Novel Psychoactive Substance Tracking - Tracking new psychoactive medicines, technologies, research chemicals, psychedelics, and novel psychoactive substances (NPS) is one of Erowid Center's areas of expertise. With the objective of educating the public on the risks and benefits associated with emerging drugs, we 1) monitor the availability, use patterns, and effects of these subst… Read more

    5. Drug Trend & Novel Psychoactive Substance Tracking - Tracking new psychoactive medicines, technologies, research chemicals, psychedelics, and novel psychoactive substances (NPS) is one of Erowid Center's areas of expertise. With the objective of educating the public on the risks and benefits associated with emerging drugs, we 1) monitor the availability, use patterns, and effects of these substances through consultation with volunteers, allied organizations, medical professionals, submissions, and online forums; 2) analyze psychoactive chemicals through our DrugsData program (tracked as a separate project); 3) coordinate between experts and researchers in the field; 4) educate writers and authors for media, news, and books; and 5) publish information about these substances, online and in print. In 2024, Erowid's DrugsData encountered 35 unidentifiable novel substances in submitted samples. With the help of a network of international experts, we were able to identify 14 of these. Erowid worked with multiple groups to monitor the contents of street 'heroin'/down/dope/fentanyl as well as cocaine and methamphetamine. Erowid helped identify and characterize contaminants, synthesis byproducts, and novel substances. We leveraged our expertise to help develop systems to mitigate the societal damage of the "opioid epidemic", improve state- and city-level drug supply monitoring, and provide facts to help public health messaging around misrepresented and contaminated street drugs.

    $40,041 spent · 7.3% of program spending

Where each dollar went · fiscal year 2024

Of every dollar it spent, 83¢ went to programs, 12¢ to management and 5¢ to fundraising.

  • Programs $551,518
  • Management $77,332
  • Fundraising $32,087

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score58 / 100
DesignationNot ranked

Score breakdown

MeasureThis organizationPoints
Operating reserves9.7 mo; 1.8 mo in cash6.7 / 25
Financial balance (median margin)−11.8%5.3 / 20
Transparency4 full 990s, latest TY202420 / 20
Program growth+1.5% / yr8.2 / 15
Track record19 years7.6 / 10
Debt load3.8% of assets10 / 10
Total57.8 → 58
Spending on programs
Not scored; America's Best needs 65%+
83%Meets

Compared with Grass Valley peers

MeasureThis organizationPeer median
Operating reserves9.7 mo3.7 mo
Typical margin−11.8%+8.7%
Spending growth+1.5% / yr+25.1% / yr
Debt load3.8%6.5%

Peers: the 5 Grass Valley mental health organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$423,518Fiscal year 20242021: $699,75020212022: $666,51920222023: $703,76820232024: $423,5182024
Expenses$660,937Fiscal year 20242021: $632,57920212022: $778,24820222023: $775,16420232024: $660,9372024
Total assets$554,990Fiscal year 20242021: $785,14020212022: $432,21920222023: $539,00720232024: $554,9902024
Total liabilities$21,305Fiscal year 20242021: $1,97920212022: $11,82420222023: $25,42020232024: $21,3052024
Fiscal year ending December 2024
Revenue$423,518
Expenses$660,937
Net income−$237,419
Net assets$533,685

Notable sources of revenue

Percent of total revenue
Contributions$260,960
Program services$157,697
Investment income$4,861
Other (net)$0

Assets / debt

Total assets$554,990
Total liabilities$21,305
Net assets$533,685

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$703,768
Expenses$775,164
Net income−$71,396
Net assets$513,587

Notable sources of revenue

Percent of total revenue
Contributions$308,191
Program services$389,041
Investment income$6,536
Other (net)$0

Assets / debt

Total assets$539,007
Total liabilities$25,420
Net assets$513,587

Compensation

Officers and key employees$199,107
Share of expenses25.7%
Fiscal year ending December 2022
Revenue$666,519
Expenses$778,248
Net income−$111,729
Net assets$420,395

Notable sources of revenue

Percent of total revenue
Contributions$288,567
Program services$366,787
Investment income$11,165
Other (net)$0

Assets / debt

Total assets$432,219
Total liabilities$11,824
Net assets$420,395

Compensation

Officers and key employees$196,456
Share of expenses25.2%
Fiscal year ending December 2021
Revenue$699,750
Expenses$632,579
Net income$67,171
Net assets$783,161

Notable sources of revenue

Percent of total revenue
Contributions$449,818
Program services$234,361
Investment income$15,571
Other (net)$0

Assets / debt

Total assets$785,140
Total liabilities$1,979
Net assets$783,161

Compensation

Officers and key employees$164,421
Share of expenses26.0%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?